Second primary malignancies in colorectal cancer patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 02 2021
02 02 2021
Historique:
received:
07
08
2020
accepted:
18
01
2021
entrez:
3
2
2021
pubmed:
4
2
2021
medline:
16
11
2021
Statut:
epublish
Résumé
The prevalence of second primary malignancies (SPMs) in the western world is continually increasing with the risk of a new primary cancer in patients with previously diagnosed carcinoma at about 20%. The aim of this retrospective analysis is to identify SPMs in colorectal cancer patients in a single-institution cohort, describe the most frequent SPMs in colorectal cancer patients, and discover the time period to occurrence of second primary tumors. We identified 1174 patients diagnosed with colorectal cancer in the period 2003-2013, with follow-up till 31.12.2018, and median follow-up of 10.1 years, (median age 63 years, 724 men). A second primary neoplasm was diagnosed in 234 patients (19.9%). Older age patients, those with early-stage disease and those with no relapse have a higher risk of secondary cancer development. The median time from cancer diagnosis to development of CRC was 8.9 years for breast cancer and 3.4 years for prostate cancer. For the most common cancer diagnosis after primary CRC, the median time to development was 0-5.2 years, depending on the type of malignancy. Patients with a diagnosis of breast, prostate, or kidney cancer, or melanoma should be regularly screened for CRC. CRC patients should also be screened for additional CRC as well as cancers of the breast, prostate, kidney, and bladder. The screening of cancer patients for the most frequent malignancies along with systematic patient education in this field should be the standard of surveillance for colorectal cancer patients.
Identifiants
pubmed: 33531585
doi: 10.1038/s41598-021-82248-7
pii: 10.1038/s41598-021-82248-7
pmc: PMC7854629
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2759Références
Cancer. 2016 Oct;122(19):3075-86
pubmed: 27377470
Pharm Res. 2008 Sep;25(9):2097-116
pubmed: 18626751
J Clin Oncol. 2014 Dec 10;32(35):4004-11
pubmed: 25267739
Breast Cancer Res Treat. 2005 Sep;93(1):91-5
pubmed: 16184464
BMC Cancer. 2017 Dec 19;17(1):871
pubmed: 29258467
Ann Surg Oncol. 2019 Jul;26(7):2037-2043
pubmed: 30949861
Cancer Med. 2018 Nov;7(11):5752-5759
pubmed: 30277023
Prostate Cancer. 2019 Feb 11;2019:4387415
pubmed: 30886751
JAMA Oncol. 2017 Feb 1;3(2):211-219
pubmed: 27787550
ESMO Open. 2017 May 2;2(2):e000172
pubmed: 28761745
Dis Colon Rectum. 2013 Feb;56(2):158-68
pubmed: 23303143
Klin Onkol. 2014;27(1):11-7
pubmed: 24635432
Radiother Oncol. 2017 Apr;123(1):139-146
pubmed: 28285840
Lancet Oncol. 2011 Apr;12(4):353-60
pubmed: 21454129
Radiat Oncol J. 2018 Jun;36(2):85-94
pubmed: 29983028
Acta Oncol. 1994;33(6):591-8
pubmed: 7946433
Oncologist. 2020 Apr;25(4):e644-e650
pubmed: 31943509
Eur J Cancer Care (Engl). 2019 Sep;28(5):e13123
pubmed: 31231898
Conn Med. 1992 Aug;56(8):411-4
pubmed: 1526142
Int J Cancer. 2011 Apr 1;128(7):1659-67
pubmed: 20503267
J Dermatol Sci. 2014 Jul;75(1):3-9
pubmed: 24680127
Eur J Cancer Prev. 2019 May;28(3):159-166
pubmed: 29668653
Dis Colon Rectum. 2018 Nov;61(11):1250-1257
pubmed: 30239394
Biomed Res Int. 2018 Aug 30;2018:6172670
pubmed: 30228986
Eur J Cancer Prev. 2005 Aug;14(4):307-8
pubmed: 16030420
Klin Onkol. 2015;28(1):30-43
pubmed: 25692753
Chest. 2005 Apr;127(4):1152-8
pubmed: 15821189
BMC Cancer. 2020 Jan 21;20(1):51
pubmed: 31964352
N Engl J Med. 2015 Dec 24;373(26):2499-511
pubmed: 26699166
J Clin Oncol. 2012 Oct 20;30(30):3734-45
pubmed: 23008293
Gastric Cancer. 2016 Apr;19(2):490-497
pubmed: 25772342
Anticancer Res. 2015 Jul;35(7):4131-4
pubmed: 26124366
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
PLoS One. 2013 Nov 12;8(11):e78709
pubmed: 24265711
Methods Mol Biol. 2009;471:85-105
pubmed: 19109776